Taysha Gene Therapies (TSHA) vs Windward Bio Group (WWB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Windward Bio Group is the larger company by market cap ($1.45 billion vs $1.21 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TSHA | WWB |
|---|---|---|
| Share price | $3.72 | $24.29 |
| Market cap | $1.21B | $1.45B |
| 1-day change | -1.33% | +1.15% |
| YTD return | -32.36% | — |
| 1-year return | -11.22% | — |
| 5-year return | -70.69% | — |
| EPS (TTM) | $-0.42 | $-1.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $9.77M | — |
| Revenue growth (YoY) | +17.28% | — |
| Net income (latest FY) | $-109.00M | — |
| Operating margin | -1130.65% | — |
| Net margin | -1115.27% | — |
| 52-week high | $7.30 | $33.99 |
| 52-week low | $3.46 | $18.35 |
| Distance from 52-week high | -49.04% | -28.55% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +249.46% | — |
| Average volume | 3.59M | 434.33K |
| Shares outstanding | 326.05M | 59.58M |
| Employees | 99 | 33 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Taysha Gene Therapies
TSHA stock →Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 99 employees
About Windward Bio Group
WWB stock →Windward Bio Group AG operates as a clinical stage biotechnology company that develops ultra-long-acting antibody medicines for patients with respiratory and dermatologic diseases. Its drug candidates WIN378, an ultra-long-acting and novel fully human monoclonal antibody, which has completed Phase I clinical study that inhibits thymic stromal lymphopoietin (TSLP); and WIN027, an ultra-long-acting bispecific antibody that is in Phase I clinical study simultaneously targets TSLP and interleukin-13 (IL-13) and two clinically validated drivers of inflammatory disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 33 employees
TSHA vs WWB FAQ
Which is bigger, Taysha Gene Therapies or Windward Bio Group?
Windward Bio Group (WWB) is larger, with a market capitalization of $1.45B compared with $1.21B for Taysha Gene Therapies (TSHA).
Are Taysha Gene Therapies and Windward Bio Group in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.